Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Qilian International Holding Group Limited QLI NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • CN • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Qilian International Holding Group Limited (QLI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.41. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $46M, -0.2%/yr average growth. Net income is $8M (loss), growing at -308.7%/yr. Net profit margin is -16.7% (negative). Gross margin is 1.3% (-13.8 pp trend).

Balance sheet: total debt is $577,850 against $43M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.18 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $51M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 75/100 (Partial), Health 100/100 (Pass), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

QLI SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — QLI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
QLI: -0.2%/yr revenue is, -308.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
QLI: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet QLI: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 5.18 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
QLI: Net profit margin is -16.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.7755-6.69
Volume330
Avg Volume (30D)22.52K
Market Cap$38.68M
Beta (1Y)1.41
Share Statistics
EPS (TTM)-0.22
Shares Outstanding$35.75M
IPO Date2021-01-12
Employees298
CEOChen Xin
Financial Highlights & Ratios
Revenue (TTM)$46.47M
Gross Profit$608.43K
EBITDA$-1.27M
Net Income$-7.78M
Operating Income$-2.61M
Total Cash$22.42M
Total Debt$577.85K
Net Debt$-6.9M
Total Assets$51.26M
Price / Earnings (P/E)-24.6
Price / Sales (P/S)0.83
Analyst Forecast
Company Info
CountryCN
ExchangeNASDAQ Global Market
CurrencyUSD
ISINKYG7307E1070

Price Chart

Track all markets on TradingView
QLI
Qilian International Holding Group Limited ↗  ·  NASDAQ Global Market
Healthcare • Drug Manufacturers - Specialty & Generic
1.78 52WK RANGE 6.69

People Also View

RGC
RGC
Regencell Bioscience Holdings Limited
$29.81
-1.00%
 PAHC
PAHC
Phibro Animal Health Corporation
$55.01
-6.79%
 ANIP
ANIP
ANI Pharmaceuticals, Inc.
$76.48
-2.31%
 SHPHF
SHPHF
Sihuan Pharmaceutical Holdings Group Ltd.
$0.19
+9.68%
 COLL
COLL
Collegium Pharmaceutical, Inc.
$34.93
-1.99%
 AQST
AQST
Aquestive Therapeutics, Inc.
$4.24
+2.17%
 PROC
PROC
Procaps Group S.A.
$1.01
+100.00%
 SSIC
SSIC
Silver Spike Investment Corp.
$10.74
+1.27%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message